Clinical Trial Update: Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase IIA proof-of-concept trial update evaluating regorafenib in biopsy-amenable Asian colorectal cancer patients. The study is conducted in Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Asian Colorectal Cancer Patients | Phase 2, Phase 3 | Status: UNKNOWN